Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00074606" target="_blank" >RIV/00159816:_____/21:00074606 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/21:10441684 RIV/00023884:_____/21:00009123 RIV/65269705:_____/21:00074606 RIV/00216224:14110/21:00122391

Výsledek na webu

<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255271" target="_blank" >https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255271</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0255271" target="_blank" >10.1371/journal.pone.0255271</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction

Popis výsledku v původním jazyce

Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica(R), Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF &lt; 40%) and HF with mid-range EF (HFmrEF) (LVEF 40%-49%). Methods and results A total of 520 patients with HFrEF and HFmrEF were enrolled in this study. Two-year all-cause mortality, heart transplantation, and/or left ventricular assist device implantation were defined as the primary endpoints (EP). A logistic regression analysis was used for the identification of predictors and development of multivariable models. The EP occurred in 14% of the patients, and these patients had higher NT-proBNP (1,950 vs. 518 ng/l; p &lt; 0.001) and hs-cTnI (34 vs. 17 ng/l, p &lt; 0.001) levels. C-statistics demonstrated that the optimal cut-off value for the hs-cTnI level was 17 ng/l (AUC 0.658, p &lt; 0.001). Described by the AUC, the discriminatory power of the multivariable model (NYHA &gt; II, NT-proBNP, hs-cTnI and urea) was 0.823 (p &lt; 0.001). Including heart failure hospitalization as the component of the combined secondary endpoint leads to a diminished predictive power of increased hs-cTnI. Conclusion hs-cTnI levels &gt;= 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF. Determining a patient&apos;s hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.

Název v anglickém jazyce

Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction

Popis výsledku anglicky

Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica(R), Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF &lt; 40%) and HF with mid-range EF (HFmrEF) (LVEF 40%-49%). Methods and results A total of 520 patients with HFrEF and HFmrEF were enrolled in this study. Two-year all-cause mortality, heart transplantation, and/or left ventricular assist device implantation were defined as the primary endpoints (EP). A logistic regression analysis was used for the identification of predictors and development of multivariable models. The EP occurred in 14% of the patients, and these patients had higher NT-proBNP (1,950 vs. 518 ng/l; p &lt; 0.001) and hs-cTnI (34 vs. 17 ng/l, p &lt; 0.001) levels. C-statistics demonstrated that the optimal cut-off value for the hs-cTnI level was 17 ng/l (AUC 0.658, p &lt; 0.001). Described by the AUC, the discriminatory power of the multivariable model (NYHA &gt; II, NT-proBNP, hs-cTnI and urea) was 0.823 (p &lt; 0.001). Including heart failure hospitalization as the component of the combined secondary endpoint leads to a diminished predictive power of increased hs-cTnI. Conclusion hs-cTnI levels &gt;= 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF. Determining a patient&apos;s hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10700 - Other natural sciences

Projekt

<a href="/cs/project/NV18-09-00146" target="_blank" >NV18-09-00146: Účinnost chodecké intervence s využitím krokoměru na fyzickou zdatnost a neurohumorální modulaci u pacientů s chronickým srdečním selháním</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS ONE

ISSN

1932-6203

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

"e0255271"

Kód UT WoS článku

000685248600043

EID výsledku v databázi Scopus

2-s2.0-85112004329